At 21.5% CAGR, CBD Oil Market Size & Share | Cannabidiol Oil Industry Report, 2020-2025 | Covid-19 Impact Analysis

In its latest report on CBD Oil Market provides a concise analysis of the recent market trends. The report further includes statistics, market forecasts and revenue estimations, which in addition highlights its status in the competitive domain as well as expansion trends adopted by major industry players.

Cannabidiol Oil (CBD Oil) Market: Global Market Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025.Cannabidiol Oil Market is valued at USD 23.37 Million in 2018 and expected to reach USD 1068.54 Million by 2025 with the CAGR of 21.5% over the forecast period.

Get sample of this report.

The detailed market intelligence report on the Global Cannabidiol Oil (CBD Oil) Market applies the most effective of each primary and secondary analysis to weighs upon the competitive landscape and also the outstanding market players expected to dominate Global Cannabidiol Oil (CBD Oil) Market place for the forecast 2019- 2025.

What is CBD Isolate, And How Is It Used?

As CBD continues to gain massive popularity across the globe, its fanatic fans don’t shy away from coming up with interesting ways to consume it. Luckily, CBD stands concrete with a market worth of over $1 billion, which is expected to cross the $5 billion mark near future. If you’re looking for one of the purest forms of CBD, we’re glad to have you here. So what exactly is CBD isolated? And what are its benefits? Here we will guide you through a quick tour of this compound.

What is CBD Isolate?

In simple words, CBD isolate is pure crystal powder that is 99% of pure CBD. This compound is only dominated by CBD. After the plant goes through the process of getting filtered from plants, waxes, chlorophyll, and oil, a finished product is CBD and nothing else.

How is it Made?

If you want to get pure CBD to isolate from hemp, it should be extracted. However, manufacturers have to go the extra mile to produce CBD isolate in its purest form. The process is very much like any other process of CBD products. The intriguing thing to note is, once the extraction is done, the concentrated material is still packed with plant nutrients. So if you want to get pure CBD, you need to make it go through a purifying process. The purification process is simple and filters out all the material. After this process, the oil is made to go through a winterization process, which further breaks down any kind of waxes and remaining plant materials. So now you’re left with 99% CBD, which is in its purest form.

How to Use CBD Isolate?

Now that you have chosen a CBD isolate, you must be wondering how to use it. In simple words, you can do anything you like. This is because CBD isolates don’t have any odor or taste, so people can use it in a variety of ways. Some of the common uses of CBD isolate consists of:

  1. Infuse it in Food Items

You will be surprised to know a lot of CBD fans love to infuse it in food items. Fanatic CBD fans often like to prepare dishes with CBD because it is helpful in treating several health conditions. If you want pure CBD, you can buy from industrialhempfarms.com.

  1. Mix it in Juices and Smoothies

One of the coolest and easiest ways is to add CBD to a glass of smoothie or drink. The most interesting benefit of CBD smoothies is, you can get the maximum benefit of this compound In liquid form. If you visit countryside American bars, you will be served cups of CBD tea and smoothies for as low as $5.

  1. Make Desserts With It

CBD can also be used in making chocolate chip cookies and brownies at home. If your loved ones are big CBD fans, you can infuse this compound in desserts to get an amazing experience. Although CBD desserts can easily be made at home, there are several vendors that sell CBD brownies online.

FDA Advances Work Related To Cannabidiol Products With Focus On Protecting Public Health, Providing Market Clarity

DISTRICT OF COLUMBIA: Over the past year, the U.S. Food and Drug Administration has embarked on a comprehensive evaluation of cannabidiol (CBD) products, with a focus on educating the public about the risks and unknowns of these products, gathering the science needed to better understand both these safety concerns and potential benefits to inform our regulatory approach, as well as taking steps when necessary to address products that violate the law in ways that raise a variety of public health concerns.

Today, we are providing updates on our efforts in this area, including several new steps in areas of education, research and enforcement with the ultimate goal of continuing to protect the public health and working to provide market clarity.

Educating the Public About Potential Risks of Using CBD

We’re seeing CBD being marketed in a number of different products, such as oil drops, capsules, syrups, food products, such as chocolate bars and teas, cosmetics and other topical lotions and creams, as well as products marketed for pets and other animals – and we understand consumers are seeking out these novel products for a variety of perceived health-related or other reasons.

But as the agency has stated before, we are concerned that some people wrongly think that the myriad of CBD products on the market have been evaluated by the FDA and determined to be safe, or that using CBD ‘can’t hurt.’ Aside from one prescription drug approved to treat two rare, severe pediatric epilepsy disorders, no other CBD products have been evaluated or approved by the FDA.

We remain focused on educating the public about the number of questions that remain regarding CBD’s safety. There may be risks that need to be considered before using CBD products outside of the monitored setting of a prescription from your health care provider.

In particular, the agency recently updated the public on concerns about potential harm from CBD products, including potential liver injury, interactions with other drugs and male reproductive toxicity, as well as side effects such as drowsiness. In addition, there is still much we do not know about other potential risks. For example, other than the approved prescription drug, we know little about the potential effects of sustained and/or cumulative use of CBD, co-administration with other medicines, or the risks to vulnerable populations like children, pregnant and lactating women, the elderly, unborn children and certain animal populations. This does not mean that we know CBD is unsafe to these populations or under these circumstances, but given the gaps in our current knowledge, and the known risks that have been identified, we also are not at a point where we can conclude that unapproved CBD products are safe for use. We encourage Americans to consult with their health care providers before using CBD products.

We will continue to expand our educational efforts on this front. This includes consumers broadly, specific populations where there are additional, important health considerations, as well as health care professionals who must understand these risks when talking to their patients. We will also continue to update our online resources for consumers, researchers and industry, as well as sustain multiple lines of communication with Congress, industry, researchers and our regulatory partners at the federal, state, local, territorial, tribal and international levels to share and collect needed information and hear a variety of perspectives.

Closing Knowledge Gaps in Both Safety and Potential Benefits

The marketplace for CBD-containing products is quickly evolving and it is critical that we work together with stakeholders and industry to develop high-quality data to close the knowledge gaps about the science, safety and quality of many of these products, as well as further evaluate any potential benefits outside of the one FDA-approved drug product to treat two rare, severe pediatric epilepsy disorders.

To address the questions and concerns we’ve already raised, we’re seeking reliable and high-quality data. This includes data on, among other things: the sedative effects of CBD; the impacts of long-term sustained or cumulative exposure to CBD; transdermal penetration and pharmacokinetics of CBD; the effect of different routes of CBD administration (e.g., oral, topical, inhaled) on its safety profile; the safety of CBD for use in pets and food-producing animals; and the processes by which “full spectrum” and “broad spectrum” hemp extracts are derived, what the content of such extracts is, and how these products may compare to CBD isolate products.

Given the importance of answering these questions, we’re exploring a number of ways to address the data gaps as quickly as possible. This includes encouraging, facilitating and initiating more research on CBD, providing venues for industry and researchers to share new data with the agency and identifying opportunities to further collaborate with our federal partners at Centers for Disease Control and Prevention, Substance Abuse and Mental Health Services Administration and National Institute on Drug Abuse on this important issue.

Importantly, the Agriculture Improvement Act of 2018 – which, among other things, changed federal law so that cannabis and cannabis derivatives with very low levels of the psychoactive intoxicating component of cannabis, delta-9 tetrahydrocannabinol (THC) are no longer controlled substances – has opened significant new opportunities for research, and as that body of research develops and grows, there will be considerably more information available. In particular, there’s been an increased interest in drug development from CBD and other compounds found in cannabis and we are working to support drug development as much as possible.

First, given all the research and activity in this space, we are taking new steps to provide a public and transparent way for stakeholders to provide new and emerging information to us in real time as it becomes available. To this end, in the coming days we are re-opening the public docket we established for our May 2019 public hearing. The docket provides a valuable conduit for submission of scientific data on CBD to the agency, so we have decided to extend the comment period indefinitely to allow the public to comment and to share relevant data with the agency. As the agency continues to move forward to explore viable pathways for CBD products outside the drug context, this extension will allow stakeholders to continue to provide relevant data as research in this area evolves.

This docket also includes a mechanism for a stakeholder to submit data or information that the stakeholder believes to be confidential. We hope that this will enable responsible industry participants, academic researchers, and other stakeholders to share relevant information with the FDA – including information about specific products, which could help inform appropriate regulatory steps.

We also are working to generate data to help inform our work in this area. For example, the FDA’s Office of the Chief Scientist recently awarded a grant to the FDA’s National Center for Toxicological Research to conduct a study to better understand the effects of CBD exposure during pregnancy. Additionally, we’ve initiated a research study in partnership with the University of Mississippi to evaluate the levels of CBD and THC in a sample of cosmetic products to assess sensitization of THC and CBD topically, and dermal penetration.

As data become available that are high-quality, reliable and relevant to our evaluation of CBD products that fall under the FDA’s purview, we will be able to refine – and, perhaps in some cases, revise – our thinking and approaches.

Monitoring the Marketplace with a Focus on Greatest Risk to Public Harm

As we work to educate the public and close the knowledge gaps to further guide our approach to CBD products, we will continue to monitor the marketplace and take appropriate action against unlawful CBD products that pose a risk of harm to the public.

We have seen many CBD products being marketed with claims of therapeutic benefit, such as treating or curing serious diseases such as cancer and Alzheimer’s disease, or other drug claims, without having gone through the drug approval process. The proliferation of such products may deter consumers from seeking proven, safe medical therapies for serious illnesses – potentially endangering their health or life.

We also have serious concerns about products that put the public at risk in other ways. For example, we are aware of the risks posed by product contaminants such as heavy metals, THC or other potentially harmful substances. We also have significant concerns about products marketed with false claims or statements such as omitted ingredients, incorrect statements about the amount of CBD, products marketed for use by vulnerable populations like children or infants, and products that otherwise put the public health at risk.

As we move forward, we are currently evaluating issuance of a risk-based enforcement policy that would provide greater transparency and clarity regarding factors the agency intends to take into account in prioritizing enforcement decisions. Any enforcement policy would need to further the goals of protecting the public and providing more clarity to industry and the public regarding the FDA’s enforcement priorities while we take potential steps to establish a clear regulatory pathway.

Conclusion

Our ongoing efforts related to CBD, including the steps we’re announcing today, are in line with our mission to protect the public, foster innovation and promote consumer confidence. We recognize the significant public interest in CBD and we must work together with stakeholders and industry to develop high-quality data to close the substantial knowledge gaps about the science, safety and quality of many of these products. We are committed to working efficiently to further clarify our regulatory approach to these products – as always, using science as our guide and upholding our rigorous public health standards.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

USDA Publishes “Economic Viability Of Industrial Hemp In The United States: A Review of State Pilot Programs”

Screenshot 2020-02-26 07.32.09

BY TYLER B. MARK, JONATHAN SHEPHERD, DAVID OLSON, WILLIAM SNELL, SUSAN PROPER, AND SUZANNE THORNSBURY

After a hiatus of almost 45 years, the 2014 Farm Bill reintroduced industrial hemp production in the United States through State pilot programs. This study documents outcomes and lessons learned from the State pilot programs and examines legal, agronomic, and economic challenges that may impact the transition from the pilot programs to economically viable commercial production.

In this publication…

FDA Warning Letters And Test Results For Cannabidiol-Related Products

MJLegal

DISTRICT OF COLUMBIA: Over the past several years, FDA has issued several warning letters to firms that market unapproved new drugs that allegedly contain cannabidiol (CBD).

As part of these actions, FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. It is important to note that these products are not approved by FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Consumers should beware purchasing and using any such products.

FDA WARNING LETTTERS

A Guide To Using CBD For Pain Management

Cannabidiol, commonly known as CBD, is a term that’s gained quite a traction in the medical world. A substance that naturally occurs in the cannabis plant, CBD doesn’t result in the “high” that is typically linked to cannabis. In fact, the “high” feeling is a result of using tetrahydrocannabinol (THC), which is another kind of cannabinoid.

So, why has CBD gained so much popularity recently? Well, studies suggest that topical CBD products, CBD oil, in particular, provide a remedy for chronic pain and decrease inflammation, pain, and discomfort linked to different health conditions.

Due to these benefits, it is a valuable alternative for people suffering from chronic pain and, hence, turn to stronger medications for relief. Such drugs, while useful, tend to result in side effects and cause dependency.

While research on CBD and its possible results are still ongoing, the future looks promising. Using CBD for pain is only going to become more common soon.

Capsules and Pills

Images: Pexels.com

Types of CBD Products

CBD is available in a variety of forms, and whichever type you choose depends on what you need to use CBD for. These forms typically include the following:

Tinctures and oils: Liquid infused with CBD is taken orally by placing it under your tongue with a dropper. This form is excellent for people who aren’t comfortable taking capsules or pills.

Lotions and creams: These topical treatments are great for joint and muscle pain. They can also be used for skin conditions, such as psoriasis and eczema.

Capsules and pills: Such forms are commonly used to treat digestive issues and seizure disorders and may take some time to take effect once ingested.

Edibles: Ingesting gummies is one of the most common ways for CBD intake due to the taste, portability, affordability, and precision. 

Vaping: This form is the fastest way to experience the effects of CBD. Once CBD is inhaled through e-cigarettes, for instance, its compounds are directly absorbed into your bloodstream.

CBD For Pain Relief

Here are four ways CBD can help with pain:

Every person’s body contains an endocannabinoid system (ECS), a cell-signaling system. According to research, what makes CBD effective is the impact it has on the endocannabinoid receptors found in a person’s immune system and brain.

These receptors are linked to a person’s cells and receive chemical signals from various stimuli and allow your cells to react. This reaction is what results in pain relief and anti-inflammation and, hence, helps manage chronic pain, such as post-trauma pain, back pain, and post-surgical pain.

Arthritis Pain Relief

Today, arthritis affects around 54 million Americans and is the leading cause of disability in the U.S. The two most common kinds of arthritis are osteoarthritis and rheumatoid arthritis.

The former is a degenerative disease that affects the bones and joints cartilage in the thumb, hip, and knee joints. The latter is an autoimmune disease where a person’s immune system attacks the joints and causes inflammation. It often occurs in the hands and feet.

While using CBD to treat pain related to arthritis does have a positive outlook, research has only been conducted on rats. Considerable research still needs to be carried out to prove if CBD is as effective in this area as it seems to be.

Cancer Treatment Pain Relief

Treatments for cancer, such as chemotherapy and radiation, come with their side effects, such as nausea, loss of appetite, and pain. According to research, CBD eases these side effects and also helps reduce inflammation and anxiety that results from these treatments.

Migraines

Throughout history, cannabis has been used as pain relief for headaches. While research isn’t specific, it does suggest that substances found in the cannabis plant result in therapeutic effects for headaches, especially migraines.

It’s important to note that these studies typically use the entire marijuana plant, which, apart from CBD, also contains THC. Hence, it is difficult to pinpoint whether these therapeutic effects are a result of THC, CBD, or both.

Side Effects

Intake of any product for medicinal purposes requires full awareness of its potential side effects. While CBD doesn’t have any significant risks associated with it, it may cause some side effects, such as:

  • Changes in weight and appetite
  • Diarrhea
  • Fatigue

Additionally, if you’re currently taking any dietary supplements, prescription medicines, or over-the-counter (OTC) drugs, CBD may interfere with their results.

Conclusion

While research is still underway, CBD may provide pain relief for people suffering from various conditions. CBD should ideally be introduced to your body in small doses and then built up from there.

Moreover, it’s vital to consult your doctor to ensure it doesn’t interfere with any other treatments you may be undergoing. Your doctor can also help you figure out the dosage that’s right for you.

As more research is conducted, the uncertainty around using CBD for pain will decrease.

Have you used CBD to treat pain or any other medical conditions? Let us know in the comments below!

Why Researchers Recommend Using CBD After A Workout

By Hannah Jones

The workout is considered as trending physical activity these days. As interest continues to grow among health and fitness trends, people have begun to look for new ways to enhance their fitness regime.

Perhaps, eating a lot of protein and taking pre and post workout supplements can help you make the most out of your workout. This is where CBD comes in. Although CBD is not classified as a health supplement by the FDA – CBD helps restore the body, including muscle building and recovery.

A group of Colorado based researchers recently conducted a study to know how the use of cannabis affects athletes. And, it was found that there exists a possible role between the plant and pain management. The study took into account cannabis use patterns and its effects in a community-based cohort of adult athletes.

AIM OF THE STUDY

Athletes typically don’t sleep well and are anxious, so, the Athlete PEACE Survey aimed at examining cannabis use patterns and subjective effects of cannabis amongst adult athletes. Besides, it also observed the pain outcomes after the treatment.  Out of 1,161 athletes who completed the survey, 301 were current cannabis users.

The researchers determined cannabis user phenotypes and also created subjective effects factors. Additionally, over half of the cannabis users reported consumption three or fewer times per week.

  • Cluster analysis identified three statistically distinct cannabis user phenotypes

1) Athletes aged forty years and above – Primarily medical CBD users

2) Mixed age athletes – Recreational Cannabis users using both THC and CBD

3) Mixed age athletes – Long-time cannabis users using primarily THC and CBD.

  • EFA (Exploratory Factor Analysis) showed three subjective effect factors:

a)     Well-being (To measure pain-relief)

b)     Calm (To measure anxiety-relief)

c)     Adverse (To measure side-effects)

The athletes exhibited the most benefit to well-being and calm with minimal adverse effects.

This methodology can be used to develop real-world evidence to inform future use of medical cannabis products.

IMPORTANT FINDINGS

The analysis revealed:

  • Three distinct cannabis user type clusters – (It intended to inform -the patterns of using cannabis by each phenotype-cluster to experience corresponding benefits)
  • The difference in subjective effects of cannabis by these cannabis user type clusters
  • Combined THC and CBD use provided the largest benefits which increased with frequent use.
  • Athletes experienced adverse effects at low frequency
  • More athletes achieved anxiety-relief as compared to ones experiencing pain-relief

In all the three clusters, positive effects were more often observed than adverse effects. However, amongst all the three clusters, long duration COMBO cluster showed the strongest positive and adverse associations to the use of cannabis. Henceforth, the full spectrum CBD oil which has CBD & THC is the most beneficial and plays a vital role in the well being and calming factors together with having low adverse effects.

The study shows that cannabis had an effect on athletes well being together with calming and adverse effects such as anxiety and paranoia.

WHAT THE RESEARCHERS HAVE TO SAY?

The cluster analysis in cannabis research focuses on the problem use behaviors. The analyses suggest that adult athletes are using cannabis responsibly and primarily for medical conditions such as pain and anxiety. In addition, current cannabis users exercised at a high frequency with about 63% exercising 5–7 days per week and 71% exercising 6–15 hours per week (data not shown), numbers that far exceed the weekly recommendation of 150 minutes per week of exercise.

The researchers hold the view that the research of cannabis use and especially for certain groups won’t be stopping anytime soon. They are more excited and enthusiastic to study cannabis use in more demographics.

Amongst all, the older adults are the fastest-growing demographic initiating cannabis use. Such research studies will also help you know how the products affect the consumers and how they’ll be used in future.

CONCLUSION

Scientific research has laid down the base to outline the possible benefits that CBD consumption can offer post workout to athletes.

Most importantly, CBD widens the therapeutic effects of THC and benefits more as a whole. It helps reduce some painful side effects caused by muscle recovery.

The effect of CBD differs from individual to individual. However, it can make a noticeable change in your workout routine or muscle soreness.

 

Study: CBD Dosing Relieves Symptoms In Patients With Anxiety Disorders

COLORADO: The daily administration of CBD is associated with sustained symptomatic relief in patients diagnosed with anxiety disorders, according to the results of a case series published in The Permanente Journal.

Investigators at the University of Colorado, Denver and Colorado State University assessed the adjunctive use of low daily doses of CBD (typically 25mg capsules) over a three-month period in a cohort of patients diagnosed with either sleep or anxiety disorders.

Researchers reported that patients experienced a “mild improvement” in sleep scores, and a larger “more sustained response to anxiety.” They also reported that “CBD appears to be better tolerated than routine psychiatric medications.”

Authors acknowledged that the therapeutic doses used in the study were far lower than those typically associated with anxiolytic action in prior clinical trials.

They concluded: “Anxiety scores decreased fairly rapidly, and this decrease was sustained during the study period. … Randomized and controlled trials are needed to provide definitive clinical guidance.”


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Cannabidiol in anxiety and sleep: A large case series,” appears in The Permanente Journal.

Cura Partners Expands Operations To Arizona

Cura supports Arizona’s medical marijuana market and gears up for additional domestic and international expansion

ARIZONA: Cura Partners, one of the largest marijuana companies in the world, known for its best-selling brands Select Oil and Select CBD, recently opened its Arizona headquarters in Phoenix, Arizona. This move signifies the company’s commitment to bringing the safest and cleanest medical marijuana products to legal U.S. and international markets. The company began offering its Select Elite and Weekender vape pens to dispensaries and Select CBD (hemp-derived cannabidiol) products to dispensaries and a few retail outlets in the state in October.

The Arizona office currently has 30 active team members, with an expected growth to 75 employees by mid-2019. In addition to Arizona, Select now operates in four U.S. states including Oregon, California and Nevada, with additional U.S. and international expansion on the horizon. “Our recent expansion to Arizona supports our mission to be the leader in this space,” said Cura President and Chief Executive Officer Cameron Forni.“We are thrilled to be providing Select products to the Arizona community and look forward to hiring local residents and bringing more superstars into our Cura family.”

The company has seen unprecedented growth, and was recently listed by Portland Business Journal as the fastest-growing private company in the state’s history. Cura also ranked no. 45 on the Inc. 5000 list of America’s fastest-growing companies, and was the first company of its kind to ever rank this high on the list. Everything the team does at Cura is built upon six core values, which are embodied by every employee: customer welfare, candor, driving results, thriving on rapid change, striving to be a superstar, and hiring and mentoring superstars.

“We look forward to working with the Arizona medical marijuana community,” said Adam Pressler, General Manager, Cura Arizona. “While we are just kicking off our production in Arizona, we have already found it to be a positive experience for our team and our colleagues. This is an emerging industry that is growing rapidly, we are thrilled to help pave the way for everyone in Arizona’s medical marijuana community.

As Cura Partners, Inc. expands to new markets, its number one priority remains providing only top-tier pesticide-free products to retailers and consumers. All Select brand products are run through a full-extended pesticide analysis as well as full-potency and microbial analysis, making Select the only marijuana company in Arizona currently utilizing these stringent testing practices. The brand has established itself as a market leader in every state it expands to by testing to its extremely strict testing regulations even when the state does not require the same level of pre-market testing.

Consumers looking for the cleanest, safest and most potent products can now find Select products in over 40 Arizona stores statewide including Harvest, The Mint, Metro Meds Dispensary, Curaleaf, Desert Rose, Sky Dispensaries and Nature’s Medicines. Select offers a wide array of products with THC levels ranging from zero percent THC in its CBD products, to more than 90 percent in its Select Elite vape pen line.

FSD Pharma Announces Launch of IBS Clinical Study

CANADA: FSD Pharma has announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics. The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously reported efficacy results from a preclinical study in rodent models which demonstrated a three-fold increased efficacy in lowering abdominal inflammation levels with the advanced combination product as compared to CBD alone.

The double-blind, randomized, placebo-controlled study will enroll 20 patients in a cross-over design to comply with the highest standards of rigorous scientific validity and certification demands of international medical regulatory authorities.

Under the terms of FSD’s strategic agreement with SciCann, the Company holds exclusive manufacturing and distribution rights for the “Steady Stomach” product in Canada.

The study’s principal investigator is Dr. Bryan Doner of Compassionate Care Certifications Centers in Pittsburgh, Pennsylvania and the CRO is Affinity Bio Partners, led by CEO Dr. Christina DiArcangelo Puller.

Dr. Raza Bokhari, CEO of FSD Pharma, stated, “This innovative clinical study aims to demonstrate the safety and efficacy of this easy-to-administer, side-effect-free therapy for a very common disease. Although rarely spoken about, IBS causes suffering to many patients around the world by dramatically reducing quality of life. The launch of this study marks another important milestone for FSD on its way to becoming a leading supplier of superior and differentiated medical, cannabis-based therapies for patients. Together with our partner SciCann, FSD is working tirelessly towards the development of novel and disruptive cannabinoid-based therapies for the world’s most under-treated diseases and irritable bowel syndrome is high on our list of target indications.”

Dr. Zohar Koren, co-founder and CEO of SciCann Therapeutics, stated, “The prevalence of irritable bowel syndrome is estimated at 10-15 percent of the global population. This is an under-diagnosed, hard-to-treat condition that causes an estimated cost to society of over US$21 billion annually in direct medical expenses and indirect costs associated with loss of productivity1. Based on our research, we believe that our proprietary “Steady Stomach” CBD combination product can serve as a new treatment standard to improve the lives of patients. We are looking forward to reporting on the results of this clinical study. ”